< Back

September, 2017

Direct Medicare Price Negotiation is Good for Payers

Healthcare Policy Decisions | September 2017

Direct Medicare Price Negotiation is Good for Payers

Reducing the biologic exclusivity period would have negative effects on physician autonomy as payers are likely to require physicians (via tier placement or utilization restrictions) to prescribe lower-cost generic or biosimilar alternatives when available. 

Direct Medicare Price Negotiation is Good for Payers

Download the research slide

 

These and other findings can be found in Health Strategies Group’s recently released research Assessment of 2017 Healthcare Policy Decisions for Biopharma August Pulse.

Key Questions Answered:

  • What are the most pressing policy questions for your organization?
  • What policies are being implemented by the new government?
  • How are your customers responding to the shifting political landscape?
  • What are the implications for biopharmaceutical companies?

Download Research Agenda

 

Visit our Healthcare Policy Decisions webpage to learn more about this research.

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.